Sentinel node biopsy in breast cancer: what the result can change

A sentinel lymph node lies on one of the first lymph drainage routes from a tumour. It is not necessarily the largest node, and it is not something a patient can identify by feeling the armpit. Sentinel node biopsy checks for cancer cells while removing a limited amount of tissue for examination. Despite the singular name, more than one sentinel node may be identified.

What information the team is seeking

In invasive breast cancer, the result helps assess regional lymph nodes and plan further treatment. It forms one part of staging. A negative result means cancer cells were not found in the examined sentinel nodes; it does not independently establish that every other organ is free of disease. A positive regional node result is not automatically stage IV cancer either.

The NCI sentinel node guide describes mapping with a tracer followed by removal and examination by a pathologist. The particular mapping method and equipment available are matters for the hospital to confirm. Before surgery, clarify whether the agreed procedure is a sentinel node biopsy rather than the vague statement “we will check the nodes”.

Why the result is not a single instruction for everyone

Cancer cells in a sentinel node do not always mean that the remaining underarm nodes must be removed immediately. The amount of involvement, breast operation, treatment already received and radiotherapy plan all matter. Some people can avoid a more extensive axillary operation, while others still need one. Another patient’s experience cannot establish which situation applies to you.

In selected circumstances, the team may also discuss omitting surgical node staging when its result would not change subsequent treatment. This is an individual decision based on the full findings, not a general reason to decline biopsy. The ASBrS axillary management guide places these changing options in their clinical context.

Why DCIS creates a different discussion

In pure DCIS, abnormal cells have not extended beyond the ducts. The question about surgical node assessment therefore differs from the question in invasive cancer. Concern about an unrecognised invasive component and the proposed breast operation are relevant. If node biopsy is suggested with DCIS, ask for the specific reason; the recommendation alone does not confirm node involvement.

Clarifying consent before the operation

Establish when the pathology result will be available and which decisions might be made during the same operation. Consent should be understandable: does it cover only the planned assessment, or also a further procedure if particular findings arise? Not every laboratory answer can be finalised in the operating theatre. A later clarification does not automatically represent a mistake.

Tell the team about previous breast or underarm surgery, earlier radiotherapy, systemic treatment and known allergic reactions. These details contribute to planning rather than merely completing an administrative form. If care was provided elsewhere, send the actual procedure records so the operation does not have to be reconstructed from memory.

Getting a usable result and recovery plan

Removing fewer nodes generally carries less risk than a more extensive underarm operation, but the risk is not zero. Possible problems include fluid collections, pain, altered sensation, restricted movement and lymphoedema. Obtain individual care instructions and a contact for increasing swelling, redness or other concerns after the procedure.

Collect the complete result: how many nodes were examined, what was found and how those findings affected the recommendation. An informal message saying “the node was clear” is not enough for the next clinician to reconstruct staging and treatment decisions.

When returning home after treatment, arrange how the report and wound-care plan will reach the local team. If another operation is recommended, the explanation should connect it to the actual pathology and the other planned treatments. This makes the value of the first procedure clear and avoids treating a positive or negative label as the whole clinical story.